A review summarizes how neutrophil-based delivery platforms use innate recruitment pathways to move therapeutics across biological barriers in inflammation and cancer. The article catalogs strategies including living neutrophils, biomimetic membranes, and extracellular vesicle formats designed to exploit neutrophil trafficking. The review emphasizes the engineering logic behind targeting: leveraging how neutrophils naturally home to inflammatory microenvironments and tumors, then coupling that movement to payload delivery. It also surveys common constraints—manufacturing consistency, off-target migration, and translational safety considerations. For pipeline teams, the key message is that neutrophil targeting is being diversified beyond single-vehicle approaches, and the evidence base is broadening across inflammatory disease and tumor models.